SynthesisInflammopharmacology2026
Anti-neuroinflammatory and neuroprotective effects of acteoside (verbascoside) in experimental models of neurodegeneration: a systematic review and meta-analysis.
Synthesis in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acteoside (verbascoside) is a phenylpropanoid glycoside widely distributed in medicinal plants and has been extensively investigated for its neuroprotective potential in preclinical models of neurological disorders; however, a comprehensive quantitative synthesis of its efficacy and underlying mechanisms has been lacking. This systematic review and meta-analysis evaluated the neuroprotective effects of acteoside across experimental models of neurodegeneration by synthesizing behavioral, biochemical, inflammatory, oxidative stress, and neurotrophic outcomes. Pooled analyses demonstrated that acteoside significantly improved behavioral performance, including anxiety-related behavior and cognitive function, as assessed using the elevated plus maze and Morris water maze paradigms. Acteoside robustly enhanced endogenous antioxidant defenses by increasing superoxide dismutase, catalase, and reduced glutathione levels, while significantly reducing lipid peroxidation, indicating effective mitigation of oxidative stress. In parallel, acteoside markedly suppressed neuroinflammatory mediators, including tumor necrosis factor-α, interleukin-6, and interleukin-1β, reduced brain water content, and attenuated glial activation, reflecting inhibition of neuroinflammatory signaling and preservation of blood–brain barrier integrity. Notably, acteoside significantly increased brain-derived neurotrophic factor levels, suggesting activation of pro-survival and synaptic plasticity pathways. Collectively, these findings demonstrate that acteoside confers robust, multitarget neuroprotection through coordinated antioxidant, anti-neuroinflammatory, and neurotrophic mechanisms, supporting its therapeutic potential for neurodegenerative and neuroinflammatory disorders.
Indexed as
Identifiers
42014645What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.